Valneva SE ADR (VALN) Stock Analysis

Valneva SE ADR (VALN) is a publicly traded company in the HEALTHCARE sector. It trades at $5.63, carries a market capitalization of $592.65M. This page summarizes the public market data, fundamentals, and frequently asked questions for VALN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Valneva SE ADR currently has a Bullish sentiment score of 0.42.

About Valneva SE ADR

Valneva SE ADR is a biotechnology company based in Saint-Herblain, France, specializing in the development and commercialization of innovative vaccines targeting infectious diseases with considerable unmet medical needs. The company's robust pipeline includes vaccine candidates for Lyme disease and chikungunya, exemplifying its commitment to addressing critical health challenges through advanced research and technology. With a strategic focus on unique and effective vaccine solutions, Valneva...

GNG Research Analysis

GNG Research scores Valneva SE ADR (VALN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VALN.

Frequently Asked Questions

Does VALN pay dividends?

Valneva SE ADR (VALN) does not currently pay a regular dividend.

What is VALN's market cap?

Valneva SE ADR (VALN) has a market capitalization of $592.65M with a current stock price of $5.63.